NCT06980649PHASE1Recruiting

Study of BHV-1300 in Graves' Disease

Biohaven Therapeutics Ltd.

Start Date

8/21/2025

Completion Date

9/1/2027

Summary

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Eligibility Criteria

Age Range: 18 years to 65 years

Key Inclusion Criteria: 1\. Participants must have serologically confirmed Graves' Disease. Key Exclusion Criteria: 1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit. 2. History of treatment with radioactive iodine or thyroid surgery.

Interventions

DRUG

BHV-1300

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Graves Disease

Locations

Site-103

South Gate, California 90280

United States

Site-100

Miami, Florida 33126

United States

Site-104

Columbus, Georgia 31904

United States

Site-108

Greenville, North Carolina 27834

United States

Site-110

Canton, Ohio 44718

United States

Site-107

Memphis, Tennessee 38119

United States

Site-109

Dallas, Texas 75246

United States

Site-106

Houston, Texas 77054

United States

Site-101

Houston, Texas 77095

United States

Site-105

Shavano Park, Texas 78231

United States

Site-004

Fitzroy, 3065

Australia

Site-011

Herston, 4029

Australia

Site-001

Kotara, 2289

Australia

Site-003

Melbourne, 3128

Australia

Site-010

Oaklands Park, 5046

Australia

Site-008

Parkville, 3050

Australia

Site-006

St Leonards, 2065

Australia

Site-002

Torquay, 3228

Australia